Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials. — VialBase Research

Summary

Negative symptoms are a core aspect of schizophrenia psychopathology for which currently available pharmacological agents have proven minimally efficacious, making intranasal administration of oxytocin a promising treatment avenue — but one where reported effects have been inconsistent across the literature for reasons that were unclear. This paper conducted a systematic review and meta-analysis of randomized clinical trials comparing oxytocin with placebo, adding a dose-response meta-analysis to test whether dosing explained the inconsistency. Random-effects meta-analyses were performed on mean changes in negative symptoms. In the initial analysis of all nine identified randomized clinical trials, intranasal oxytocin showed no significant effect on negative symptoms. For higher doses (>40-80 IU), a beneficial effect on negative symptoms was found with a moderate effect size — but this effect disappeared after exclusion of one outlier study, revealing that the apparent high-dose benefit rested on a single trial. The dose-response model predicted that higher doses of oxytocin may be more efficacious for negative symptoms. For positive symptoms, no beneficial effect was found in the main meta-analysis, though the dose-response analysis again suggested a potential advantage of higher doses. The authors’ summary judgment is that the results show no consistent beneficial effect of intranasal oxytocin for either negative or positive symptoms, that the dose-response meta-analysis does not allow firm conclusions, and that any future studies would need to make a deliberate effort to reach adequate CNS concentrations for a sufficient duration.

Key Findings

• Nine randomized clinical trials were identified and pooled using random-effects meta-analysis, with a separate dose-response meta-analysis on mean changes in negative symptoms
• In the initial analysis of all nine trials, intranasal oxytocin showed no significant effect on negative symptoms of schizophrenia
• A beneficial effect of moderate effect size emerged for higher doses (>40-80 IU) — but disappeared after exclusion of one outlier study, exposing the fragility of that subgroup result
• For positive symptoms, no beneficial effect of oxytocin was found in the main meta-analysis
• The dose-response meta-analysis predicted higher doses may be more efficacious for both negative and positive symptoms, but the authors state directly that it “does not allow drawing any firm conclusions”
• The authors attribute the overall failure in part to pharmacokinetics, noting that future studies would require an effort to reach adequate CNS concentrations for a sufficient duration — an acknowledgment that intranasal delivery may not be getting enough oxytocin into the brain

Relevance to Oxytocin

This synthesis matters for Oxytocin beyond its psychiatric indication because of what it reveals about the intranasal route generally. Across nine trials there was no consistent benefit, and the one encouraging signal — moderate benefit at doses above 40 IU — evaporated when a single outlier trial was removed. That is exactly the kind of finding that gets cited as “high-dose oxytocin improves negative symptoms” with the outlier caveat quietly dropped; the honest statement is that the high-dose effect was not robust. The authors’ closing note about needing to reach adequate CNS concentrations for a sufficient duration is the more transferable insight: it is an open question whether intranasal dosing meaningfully raises central oxytocin at all, which bears directly on every intranasal application marketed for mood, bonding, or behavior. Read together with the negative obesity RCT (PMID 38815173) and the tentative social cognition meta-analysis (PMID 29032324), the pattern across well-conducted intranasal oxytocin trials is consistently null or inconclusive.

Citation

Sabe M, Zhao N, Crippa A, et al. Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials. The international journal of neuropsychopharmacology. 2021;24(8):601-614. doi:10.1093/ijnp/pyab020.

See Also

• Parent compound: Oxytocin